News

Merck has reported a net income of $1.64 billion, or $0.78 per diluted share, for the fourth quarter of 2008, compared to a net loss of $1.63 billion,

Under the terms of the merger agreement, JLL will commence a tender offer to purchase all of the outstanding shares of PharmaNet at a price of $5 per

PTC Therapeutics, a biopharmaceutical company, has successfully completed patient enrollment in its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy. Accrual

The study is an open-label Phase I clinical trial of the safety and tolerability of a single infusion of autologous CD4+ T cells genetically modified at the CCR5

The supplemental biologics license application (sBLA), submitted to the FDA in December 2008, was based on a re-analysis and resubmission of data from a pivotal Phase III acute

Zealand Pharma, a Denmark-based biopharmaceutical company, has advanced ZP1848, a glucagon-like peptide-2 agonist, into Phase I clinical trials. ZP1848, a peptide which incorporates the company’s proprietary SIP technology,

Cenix will apply its expertise in combining high throughput applications of RNAi-based gene silencing, with high content phenotypic analyses in what will be a genome-scale screen using cultured

Revenues for the fourth quarter down 2% from the previous year, totaling $396.8 million. Excluding a 4% unfavorable impact from changes in foreign currency, revenues in the quarter

The Carillon system is a percutaneous treatment for functional mitral regurgitation. The CE Mark approval is an important milestone for Cardiac Dimensions, allowing the company to market the